光峯科技(688007.SH):公司初步向A股上市公司華勤技術、港股上市公司舜宇光學集團等AR產業鏈上下游公司提供過小批量的模組樣機
格隆匯10月28日丨光峯科技(688007.SH)近期投資者互動記錄顯示,公司此前公佈了自研的全球首個PPI破萬AR光學模組,可用於AR眼鏡,能夠解決行業對輕量化可適應日常佩戴的痛點,滿足室內室外多適用場景的亮度需求。當前,AR產業整體仍處於探索的初期階段,公司初步向A股上市公司華勤技術、港股上市公司舜宇光學集團等AR產業鏈上下游公司提供過小批量的模組樣機,用於項目預研及產品預研發。AR顯示是公司中長期探索方向之一,敬請關注後續進展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.